Lung Cancer. Prevention, Management, and Emerging Therapies

About this book

• Provides full coverage of established and emerging therapies, including novel targeted and antiangiogenic agents
• Evaluates the mechanisms of drug resistance and the therapeutic potential of new targets
• Integrates molecular biology into strategies for prevention and treatment of lung cancer
• Presents the most current data on pharmacogenetics in prediction of disease and efficacy and toxicity of chemoradiotherapy
• Offers the most up-to-date information on front line therapy and therapy for previously treated patients
• Gives critical insight into the design and optimization of clinical trials

This comprehensive resource provides authoritative knowledge of the most up-to-date prevention and treatment strategies for thoracic malignancies. Established and investigational therapies are placed in the context of tumor biology for a full understanding of the pharmacogenetics, etiology, and changing epidemiology of lung cancer. Expert clinicians detail the function of predictive and prognostic factors in the utilization of chemo-radiotherapy, adjuvant and neoadjuvant treatment, and targeted agents. The promises and potential pitfalls of investigational strategies are evaluated with exceptional insight and clarity, with unique attention paid to the mechanisms of drug resistance and targets for lung cancer treatment and prevention.

Lung Cancer: Prevention, Management, and Emerging Therapies engages the entire spectrum of therapeutic modalities with focus on systemic approaches. Disease coverage includes newly diagnosed and recurrent non-small cell lung cancer, small cell carcinoma, mesothelioma, thymoma, and thymic carcinoma. Critical examination of the impact, methodology, and design of clinical trials is presented along with new paradigms for personalized approaches and individual risk assessment.

Written for » Research

Keywords » Antiangiogenesis - Cancer - Carcinoma - Clinical trials - Lung - Malignancy - Mesothelioma - Molecular biology - Non-small cell lung cancer (NSCLC) - Novel Agents - Oncology - Prevention - Resistance - Small cell lung cancer (SCLC) - Targeted Agents - Thoracic Malignancies - Thymic carcinoma - Thymoma - Treatment - Tumor

Related subjects » Internal Medicine - Oncology & Hematology - Radiology

Table of contents

1.Molecular pathology of lung cancer: Alejandro Corvalan and Ignacio Wistuba
2.Tumor microenvironment: Tonya C. Walser, Jane Yanagawa, Edward Garon, Jay M. Lee, Steven Dubinett
3.Racial and ethnic diversity in lung cancer: Carol J. Etzel, Sumesh Kachroo
4.Pharmacogenetics of lung cancer: Xifeng Wu, Jian Gu
5.Lung cancer prevention Nir Peled, Robert L. Kieth, Fred Hirsch
6.Adjuvant and neoadjuvant therapy of non-small cell lung cancer: Katherine Pisters
7.Chemoradiotherapy for inoperable non-small cell lung cancer: James Cox and David J. Stewart
8.Management of advanced non-small cell lung cancer- front line treatment: William N. William Jr. and David J. Stewart
9.Chemotherapy in previously-treated patients with non-small cell lung cancer: Frank V. Fossella
10.Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer: Paul Wheatley-Price and Frances A, Shepherd
11.Angiogenesis inhibitors in lung cancer : Leora Horn and Alan Sandler
12.Other molecular targeted agents in non-small cell lung cancer: Benjamin Besse and Jean Charles Soria
13.Vaccine therapy for lung cancer: John Nemunaitis and Jack Roth
14.Gene-based therapies for lung cancer: John Nemunaitis and Jack Roth
15.Lung cancer resistance to chemotherapy: David J. Stewart
16.Small cell carcinoma: Emer Hanrahan and Bonnie Glisson
17.Mesothelioma: Mary Frances McAleer, Reza J. Mehran, and Anne Tsao
18.Advances in oncology clinical research statistical and study design methodologies: B. Nebiyou Bekele
19.Palliative care for patients with lung cancer: David Hui and Eduardo Bruera
20.The future of lung cancer: Sophie Sun, Joan H. Schiller, Monica Spinola, John Minna